Cargando…

Galantamine protects against beta amyloid peptide-induced DNA damage in a model for Alzheimer's disease

Detalles Bibliográficos
Autores principales:	Castillo, Willian O., Aristizabal-Pachon, Andres Felipe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514865/ https://www.ncbi.nlm.nih.gov/pubmed/28761423 http://dx.doi.org/10.4103/1673-5374.208572

Ejemplares similares

A Galantamine–Curcumin Hybrid Decreases the Cytotoxicity of Amyloid-Beta Peptide on SH-SY5Y Cells
por: Mladenova, Kirilka, et al.
Publicado: (2021)

Phosphorylation of amyloid beta (Aβ) peptides – A trigger for formation of toxic aggregates in Alzheimer's disease
por: Kumar, Sathish, et al.
Publicado: (2011)

The tip of the iceberg? The underestimated potential of non-canonical beta-amyloids for Alzheimer’s disease
por: Busch, Lukas, et al.
Publicado: (2023)

Protective Effect of Galantamine against Doxorubicin-Induced Neurotoxicity
por: Alsikhan, Rawan S., et al.
Publicado: (2023)

Bayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's disease
por: Richard, Edo, et al.
Publicado: (2021)

Plasma amyloid-beta oligomer and phosphorylated tau: diagnostic tools for progressive Alzheimer’s disease
por: An, Seong Soo A., et al.
Publicado: (2023)

Pharmacological aspects of galantamine for the treatment of Alzheimer's disease
por: Kim, Jae Kwang, et al.
Publicado: (2017)

Recent advancements toward non-invasive imaging of retinal amyloid-beta for early detection of Alzheimer’s disease
por: Wang, Liang, et al.
Publicado: (2022)

Beta‐amyloid pore linked to controlled calcium influx into the cell: A new paradigm for Alzheimer's Disease
por: Pannuzzo, Martina
Publicado: (2021)

Pharmacological investigations of new galantamine peptide esters
por: Tsvetkova, Dobrina, et al.
Publicado: (2014)

Cyclic adenosine monophosphate-elevating agents inhibit amyloid-beta internalization and neurotoxicity: their action in Alzheimer’s disease prevention
por: Gopalakrishna, Rayudu, et al.
Publicado: (2023)

Galantamine protects against lipopolysaccharide-induced acute lung injury in rats
por: Li, G., et al.
Publicado: (2015)

Galantamine protects against synaptic, axonal, and vision deficits in experimental neurotrauma
por: Naguib, Sarah, et al.
Publicado: (2019)

Finding chemopreventatives to reduce amyloid beta in yeast
por: Macreadie, Ian G., et al.
Publicado: (2016)

Therapy of addition for Alzheimer's Disease: combination with galantamine and memantine
por: Zarra, Julio, et al.
Publicado: (2010)

Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease
por: Seltzer, Ben
Publicado: (2010)

Galantamine plasma concentration and cognitive response in Alzheimer’s disease
por: Lin, Yi-Ting, et al.
Publicado: (2019)

Protection against Prenatal Alcohol-Induced Damage
por: Spong, Catherine Y
Publicado: (2006)

Targeting amyloid precursor protein shuttling and processing - long before amyloid beta formation
por: Arbor, Sage
Publicado: (2017)

Oxidative stress and the amyloid beta peptide in Alzheimer’s disease
por: Cheignon, C., et al.
Publicado: (2017)

Anti-amyloid: An antibody to cure Alzheimer’s or an attitude
por: Osborne, Olivia M., et al.
Publicado: (2023)

Dose and plasma concentration of galantamine in Alzheimer's disease - clinical application
por: Wattmo, Carina, et al.
Publicado: (2013)

Clearance of amyloid‐beta with bispecific antibody constructs bound to erythrocytes
por: Taylor, Ronald P., et al.
Publicado: (2020)

The effects of amyloid-beta on hippocampal glutamatergic receptor and transporter expression
por: Kwakowsky, Andrea, et al.
Publicado: (2020)

Metformin and the ATM DNA damage response (DDR): Accelerating the onset of stress-induced senescence to boost protection against cancer
por: Menendez, Javier A., et al.
Publicado: (2011)

Combined treatment with memantine and galantamine-CR compared with galantamine-CR only in antidementia drug naïve patients with mild-to-moderate Alzheimer's disease
por: Peters, Oliver, et al.
Publicado: (2015)

Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease
por: Roda, Alejandro R., et al.
Publicado: (2022)

Oxidation of Methionine-35 in Alzheimer’s amyloid-beta peptide and the aggregation of the oxidized peptide
por: Friedemann, Merlin, et al.
Publicado: (2015)

Amyloid beta is an early responder cytokine and immunopeptide of the innate immune system
por: Weaver, Donald F.
Publicado: (2020)

The Prediction of Response to Galantamine Treatment in Patients with Mild to Moderate Alzheimer’s Disease
por: Ohnishi, Takashi, et al.
Publicado: (2014)

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
por: Siddique, Yasir Hasan, et al.
Publicado: (2022)

Protective Factors Modulate the Risk of Beta Amyloid in Alzheimer's Disease
por: Zhou, Bin, et al.
Publicado: (2020)

PARP-1 Modulates Amyloid Beta Peptide-Induced Neuronal Damage
por: Martire, Sara, et al.
Publicado: (2013)

TDP-43 and amyloid precursor protein processing: implications for Alzheimer’s disease
por: Hicks, David A.
Publicado: (2020)

Anti-amyloid therapies for Alzheimer disease: finally, good news for patients
por: Ramanan, Vijay K., et al.
Publicado: (2023)

Protective potential of glucagon like peptide 2 (GLP-2) against the neurodegeneration
por: Amato, Antonella, et al.
Publicado: (2019)

Resistant and Resilient mutations in protection against familial Alzheimer’s disease: learning from nature
por: Sepulveda-Falla, Diego
Publicado: (2023)

Galantamine ameliorates experimental pancreatitis
por: Thompson, Dane A., et al.
Publicado: (2023)

The novel amyloid-beta peptide aptamer inhibits intracellular amyloid-beta peptide toxicity
por: Wang, Xu, et al.
Publicado: (2013)

Hypothesis: apo‐lactoferrin–Galantamine Proteo‐alkaloid Conjugate for Alzheimer's disease Intervention
por: Akilo, Olufemi D., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ejljcrnrq6dgs7jr44pljhcqv8